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Despite early diagnosis, a large proportion (up to 40%) of breast
cancer patients will develop metastatic disease that is incurable
with conventional treatments (Hortobagyi and Piccart-Gebhart,
1996). The choice of appropriate therapy for metastatic breast
cancer is determined by several factors: pace of relapse (influ-
enced in part by the interval between initial presentation and first
relapse), hormone receptor status, previous treatment, presence or
absence of visceral involvement, age and fitness (including co-
morbid disease), patient preference and healthcare budgets.
Conventional chemotherapy regimens based on cyclophos-
phamide, 5-fluorouracil (5-FU) and methotrexate (CMF) or an
anthracycline (FAC, FEC) achieve response rates of 40–80% in
chemotherapy-naïve patients, although further relapse is the rule,
usually within months of stopping treatment. Moreover, the
increasing use of chemotherapy, particularly anthracycline-based
regimens, in the adjuvant setting means that new treatment options
are required for metastatic disease. Several agents have been
developed in recent years, including the taxoids (paclitaxel and
docetaxel) and vinorelbine, and these have become the second-line
treatments of choice in many countries (Livingston et al, 1997;
Archer et al, 1998; Carlson, 1998; Ray-Coquard et al, 1998; Valero
et al, 1998). 
The oral fluoropyrimidine, capecitabine, has been developed as
an enzymatically activated, tumour-selective agent, thereby
increasing tumour concentrations of active drug and limiting expo-
sure of normal tissue to the toxic effects of chemotherapy. Another
important objective in developing capecitabine was to mimic
continuous infusion 5-FU, for which response rates of 12% have
been reported in heavily pretreated patients (Ng et al, 1994; Ragaz
et al, 1997). This review examines oral fluoropyrimidines as an
alternative or an addition to vinorelbine/taxoid therapy that offers
metastatic breast cancer patients acceptable efficacy with good
tolerability and ease of use. In particular, the role of capecitabine is
examined as it offers the advantages of oral administration at
home. 
NEW TREATMENT APPROACHES FOR
METASTATIC BREAST CANCER 
Taxoids 
The taxoids are being used increasingly, either alone or in combi-
nation with other agents, in breast cancer patients whose disease
has relapsed after adjuvant chemotherapy or as first-line
chemotherapy for metastatic disease. Studies in patients who have
received extensive previous chemotherapy have shown response
rates in the range of 20–38% with paclitaxel doses of 135–
300 mg/m2 every 3 weeks, and in the range of 35–58% with
docetaxel doses of 100 mg/m2 every 3 weeks (D’Andrea and
Seidman, 1997). Two prospective, randomized, phase III trials
have demonstrated that docetaxel achieves superior response rates
compared with either mitomycin plus vinorelbine (Nabholtz et al,
1999) or doxorubicin monotherapy (Chan et al, 1999) in anthracy-
cline-resistant breast cancer patients. The median time to disease
progression and overall survival achieved with docetaxel were
significantly longer than those achieved with mitomycin plus
vinorelbine (Nabholtz et al, 1999) and equivalent to those
achieved with doxorubicin (Chan et al, 1999). 
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doi: 10.1054/ bjoc.2001.1819 available online at http://www.idealibrary.com on  http://www.bjcancer.comA large number of studies have investigated paclitaxel in
patients who have received little or no previous chemotherapy. Not
surprisingly, response rates are higher than those seen when 
paclitaxel is used as second-line therapy (Seidman et al, 1995).
Objective response rates range from 29–62%, and similar response
rates have been reported to those of docetaxel (D’Andrea and
Seidman, 1997). These response rates are similar to those achieved
with conventional combination regimens used in breast cancer,
although paclitaxel may be associated with less myelosuppression
at equally cytotoxic doses (Bishop et al, 1997). 
Vinorelbine 
To data there have been limited alternatives to paclitaxel and
docetaxel in patients with relapsed or advanced breast cancer.
Vinorelbine, a third-generation vinca alkaloid, has demonstrated
good activity in advanced breast cancer, resulting in objective
response rates of 16–17% in patients with anthracycline-resistant
or -refractory disease (Degardin et al, 1994; Jones et al, 1995;
Livingston et al, 1997), suggesting incomplete cross-resistance
between vinorelbine and the anthracyclines. Objective response
rates of up to 25% have been reported when vinorelbine is admin-
istered with granulocyte colony-stimulating factor support in
relapsed patients (Livingston et al, 1997). As first- and second-line
therapy, vinorelbine achieves objective response rates of 35–41%
(Fumoleau et al, 1993; Romero et al, 1994; Weber et al, 1995) and
24–32% (Roché et al, 1990; Weber et al, 1995), respectively. The
dose-limiting toxicity in these studies was myelosuppression and
other toxicities included phlebitis, peripheral neuropathy and
myalgia. Many clinicians find that vinorelbine is an attractive
alternative to taxoids in older or less fit patients. 
It has been suggested from preclinical studies that a combina-
tion of taxoids and vinca alkaloids may be synergistic (Schiff and
Horwitz, 1980) as a result of the differing activities of both types
of agent on microtubule assembly. Studies of vinorelbine in
combination with taxoids are ongoing (Livingston et al, 1997). 
5-FU 
The feasibility of treating anthracycline-refractory breast cancer
patients with continuous 5-FU infusion has been demonstrated.
Hansen et al (1987) reported that in 25 patients with extensive
pretreatment (24 had received previous doxorubicin and 23
previous bolus 5-FU), who were treated with continuous low-dose
5-FU infusion, an objective response was achieved in 8 patients
(32%). Side effects included hand-foot syndrome, mucositis, diar-
rhoea, and nausea and vomiting, but toxicity was easily manage-
able. The risk of these adverse effects is increased in patients with
decreased dihydropyrimidine dehydrogenase (DPD) activity (Lu
et al, 1998; Johnson et al, 1999). The efficacy of continuous 5-FU
infusion reported in the study by Hansen et al was confirmed by
Jabboury et al (1989) and Huan et al (1989). Unfortunately,
continuous infusion therapy is labour intensive, inconvenient for
the patient and is associated with complications and additional
costs related to the need for central venous access. Therefore there
is a strong medical need for an oral fluoropyrimidine which is
capable of mimicking continuous 5-FU infusion. 
Simple, convenient, oral chemotherapy regimens may be advan-
tageous in many ways (DeMario and Ratain, 1998). In particular, a
recent questionnaire-based study reported that most patients (89%)
preferred oral to intravenous palliative chemotherapy provided
that efficacy was maintained (Liu et al, 1997). Of the patients
questioned in the study, 46% had previously received i.v.
chemotherapy and 9% had previously been treated with oral
agents, with 6% of patients having prior experience of both oral
and i.v. chemotherapy. The main reasons for preferring oral
chemotherapy were convenience, problems with intravenous lines
and the ability to receive oral chemotherapy outside the clinic
environment, indicating that patients with a limited life
expectancy want to maintain as normal a life as possible. 
CAPECITABINE IN METASTATIC BREAST
CANCER 
The limitations of 5-FU prompted the development of a fluoro-
pyrimidine derivative that could be given orally and would be acti-
vated preferentially in tumour tissue, thereby increasing tumour
concentrations of active drug while minimizing exposure of
normal tissue. Capecitabine is the first of a new class of fluoropy-
rimidines rationally designed as an oral, enzymatically activated
fluoropyrimidine carbamate capable of mimicking continuous
infusion 5-FU. The activation of capecitabine preferentially in
tumour tissue results in higher intratumoral concentrations of 
5-FU (Schüller et al, 2000). 
Capecitabine is not cytotoxic itself and requires conversion to 
5-FU through 3 sequential enzyme steps (Figure 1). The interme-
diates 5¢-deoxy-5-fluorocytidine (5¢-DFCR) and 5¢-deoxy-5-fluo-
rouridine (5’-DFUR) are also inactive. Thymidine phosphorylase,
the enzyme involved in the final activation step, is active predom-
inantly in tumour tissues, including colorectal, breast, cervical and
ovarian cancers, and is present at significantly lower concentra-
tions in adjacent normal tissue (Miwa et al, 1998). The carbamate
structure of capecitabine allows the drug to be administered orally:
absorption is rapid and extensive, and the compound passes
unchanged into the liver for the first step in its activation (Budman
et al, 1998; Judson et al, 1999). 
Following administration of capecitabine to animals bearing
human cancer xenografts, significantly higher concentrations of 
5-FU were observed in tumour tissue (127-fold) than in plasma,
but no selective distribution was seen following 5-FU administra-
tion (Ishikawa et al, 1998a). Capecitabine has shown significantly
greater activity than 5-FU or UFT (uracil plus tegafur) in human
tumour xenograft models when both drugs were administered at
their maximum tolerated doses: tumour growth was inhibited by
> 50% in 18 of 24 (75%) xenograft lines treated with capecitabine
but in only one of 24 (4%) xenograft lines treated with 5-FU and 5
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Figure 1 Enzymatic activation of capecitabine to 5-FU via its inactive
intermediates 5¢-deoxy-5-fluorocytidine (5¢-DFCR) and (5¢-deoxy-5-
fluorouridine (5¢-DFUR) of 24 (21%) xenograft lines treated with UFT (Ishikawa et al,
1998b). 
Dose-finding studies of capecitabine as a single agent
and in combination regimens 
Capecitabine has been evaluated in a number of phase I clinical
studies as either intermittent (2 weeks’ treatment followed by 1
week’s rest) (Mackean et al, 1998) or continuous monotherapy
(Budman et al, 1998). It has also been studied in combination with
leucovorin (Cassidy et al, 1998), paclitaxel (Khoury et al, 1998;
Villalona-Calero et al, 1999) or docetaxel (Pronk et al, 2000) in
patients with a range of locally advanced or metastatic tumours
(predominantly breast and colorectal cancer) whose disease had
relapsed or was resistant to conventional chemotherapy. As mono-
therapy, the maximum tolerated dose was found to be 3000 mg/m2
daily for the intermittent regimen and 1657 mg/m2 daily for the
continuous regimen. The most common dose-limiting toxicities
were diarrhoea, hand-foot syndrome, nausea and vomiting, and
there was only minimal myelosuppression and no neurotoxicity at
these doses. All toxicities were reversible. The doses recom-
mended for phase II studies were 1255 mg/m2 twice daily for 
the intermittent regimen and 667 mg/m2 twice daily for the contin-
uous regimen. The intermittent regimen was highly active and 
well tolerated, and allowed greater cumulative doses to be given 
as shown in a randomized, phase II trial (Van Cutsem et al,
2000). 
As combination therapy with paclitaxel 175 mg/m2 every 3
weeks, intermittent doses of capecitabine 1000 mg/m2 twice daily
were dose limiting in 3 of 6 patients treated. No dose-limiting toxi-
cities were seen in 8 patients treated with capecitabine 825 mg/m2
twice daily (Khoury et al, 1998). Response rates were promising in
this study, with a partial response observed in 5 of the 10 evaluable
patients. 
A further phase I trial evaluated escalating doses of docetaxel
(75, 85 and 100 mg/m2 every 3 weeks) in combination with inter-
mittent, fixed-dose capecitabine therapy (825 mg/m2 twice daily
for 2 weeks) in the first phase of the trial, followed by a second
phase during which increased doses of capecitabine (1000 and
1250 mg/m2 twice daily for 2 weeks) were given in combination
with a fixed dose of docetaxel (Pronk et al, 2000). Grade 2
asthenia was considered to be dose limiting at the 1000/100 mg/m2
dose level. The schedule of capecitabine 1250 mg/m2 twice daily
for 14 days plus docetaxel 75 mg/m2 every 3 weeks was selected
for further evaluation in a phase III trial, which has recently been
reported (O’Shaughnessy et al, 2000). 
Efficacy in metastatic breast cancer patients 
Capecitabine has been investigated in an open-label, multicentre,
phase II trial of patients (163 patients enrolled, 162 patients
treated) with locally advanced or metastatic breast cancer whose
disease had progressed with previous paclitaxel chemotherapy
(Blum et al, 1999). Patients included in the trial were heavily
pretreated: 91% had received prior anthracycline treatment, 82%
had received prior 5-FU-based therapy and the mean number of
prior chemotherapeutic agents was 4.7. Capecitabine (1255
mg/m2) was administered twice daily for 14 days followed by a 7-
day rest period. Patients who responded or had stable disease after
6 weeks’ therapy (2 cycles) could continue treatment until disease
progression or unacceptable toxicity. 
The objective response rate for the study was 20% (32/162),
which included 3 complete responses (Table 1). Stable disease was
reported in 43% (70/162) of patients. Most responses occurred
after the first 4 cycles of treatment. The response rate was consis-
tent across a number of subpopulations, including those patients
who received capecitabine as third-or fourth-line treatment (18%
and 20%, respectively), showing that the drug is effective in a
range of settings. Furthermore, in a subgroup of 42 patients with
metastatic breast cancer that was both paclitaxel- and anthracy-
cline-resistant, the objective response rate was 29%, which is
particularly encouraging as response rates to salvage agents are
usually lower in patients with established resistance. 
The median duration of response was 7.9 months and median
time to progression was 3.0 months in patients with measurable
disease (n = 135). Median survival time was 12.6 months for the
entire population. This compares favourably with the 10.5-month
median survival time reported by Valero et al (1998) for docetaxel
in patients with paclitaxel-resistant disease. 
In the capecitabine study, pain, analgesic consumption and
performance status were documented using a ‘Clinical Benefit
Response’ (CBR) score. Positive responses for the 3 individual
parameters were defined as follows: ³50% reduction in pain inten-
sity in patients with baseline pain >20 mm on a visual analogue
scale; ³70 mg morphine equivalents per week; improvement of at
least 20 points in Karnofsky Performance Status. A positive
overall CBR was defined as a major improvement lasting for at
least 4 consecutive weeks in at least one of the predefined 
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Table 1 Efficacy in 3 phase II trials evaluating capecitabine as third-, second- and first-line treatment for metastatic breast cancer 
Efficacy parameter 
Trial Response rate (%) Complete response rate (%) Median TTP (months) 
Previous paclitaxel (Blum et al, 1999) 
Capecitabine (n = 162) 20 2 3.0 
Previous anthracyclines (RCT) (O’Reilly et al, 1998) 
Capecitabine (n = 22) 36 (95% Cl: 17–59%) 14 3.0 
Paclitaxel (n = 19) 26 (95% Cl: 9–51%) 0 3.1 
First-line (RCT) (Aapro, 2000) 
Capecitabine (n = 61) 30 (95% Cl: 19–43%) 5 4.1 
CMF (n = 32) 16 (95% Cl: 5–33%) 0 3.0 
RCT = randomized, controlled trial; CMF = cyclophosphamide, methotrexate and 5-FU; TTP = time to disease progression. parameters with all other parameters remaining stable. Overall
CBR scores were positive (improvement in one parameter) for 29
of the 147 evaluable patients (20%) and 45 patients (31%)
remained stable, regardless of ability to achieve a response.
Cancer-related pain was reduced in 24 of the 51 patients (47%)
who were able to achieve a positive response, i.e. >20 mm base-
line pain, and opioid requirements were reduced in 22 of the 74
patients (30%) who were able to achieve a positive response. 
Capecitabine was well tolerated in this study. Most adverse
events were mild to moderate in intensity. Grade 3/4 toxicities
included diarrhoea (14% of patients), hand-foot syndrome (10%,
grade 3 only), fatigue (7%), nausea (4%), vomiting (4%) and
stomatitis (3%). The incidence of neutropenia (3%) and neuro-
toxicity (1%) was low. No alopecia was reported, and hair growth
occurred in some patients with alopecia at baseline. Grade 4 toxi-
city was reported in only 4% of patients. All adverse events were
manageable by treatment interruption and, if necessary, dose
reduction. Dose reduction did not affect efficacy. Adverse events
led to withdrawal of 7% of women from the study, and there were
no treatment-related deaths. These results demonstrate that
capecitabine has high activity in heavily pretreated metastatic
breast cancer and is well tolerated compared with other regimens. 
The efficacy of capecitabine has also been investigated in an
open-label, randomized, phase II study of patients with anthracy-
cline-pretreated advanced breast cancer (O’Reilly et al, 1998).
Paclitaxel was used as a reference arm in this study to ensure the
absence of recruitment bias. Patients were randomized to receive
one of 3 treatments: oral capecitabine either in a continuous
schedule at a dose of 667 mg/m2 twice daily on days 1–21 (n = 2),
or capecitabine in an intermittent schedule 1255 mg/m2 twice daily
on days 1–14 (n = 22), or paclitaxel 175 mg/m2 on day 1 (n = 20)
of a 3-week cycle. 
Unfortunately, this study was discontinued prematurely because
patients refused to be randomized since they had a clear preference
for either an established intravenous cytotoxic or an investiga-
tional oral agent. The continuous regimen was discontinued
following the selection of the intermittent regimen for further clin-
ical development. However, the results obtained for capecitabine
were encouraging (Table I). There were 3 complete responses and
an overall objective response rate of 36% (95% CI: 17–59%) in
patients receiving the intermittent schedule of capecitabine. An
objective response rate of 26% (95% CI: 9–51%) was observed in
patients receving paclitaxel, with no complete responses. Median
time to progression was 3.0 months with capecitabine and 3.1
months with paclitaxel. 
Grade 3/4 toxicity for treatment-related clinical adverse events
was reported in 58% of patients receiving paclitaxel and in 23%
receiving capecitabine. Likewise, the incidence of grade 3/4
neutropenia was higher in the paclitaxel group (53%) than in the
capecitabine group (9%). Although this study was discontinued
prematurely because of recruitment issues, the results suggest that
capecitabine shows promising activity in patients with anthracy-
cline-pretreated breast cancer. 
Another randomized, phase II trial in metastatic breast cancer
investigated the efficacy and tolerability of capecitabine as first-
line treatment for metastatic breast cancer in women aged 55 years
or older (Aapro, 2000). 95 patients were randomized (2:1) to either
intermittent capecitabine treatment (1255 mg/m2 twice daily for 14
days followed by a 7-day rest period) or low-dose CMF (cyclo-
phosphamide 400 mg/m2, methotrexate 40 mg/m2, 5-FU 600 mg/
m2) administered intravenously on day 1 of each 21-day cycle. 
A response rate of 30% (95% CI: 19–43%) was observed in 61
patients treated with capecitabine, compared with 16% (95% CI:
5–33%) in the CMF group (n = 32) (Table 1). 3 patients receiving
capecitabine achieved complete responses, whereas there were no
complete responses with CMF. The median survival time was 21.6
months with capecitabine compared with 17.2 months in patients
receiving CMF. As a randomized, phase II study, this trial was not
powered to identify a statistically significant difference in survival
between the 2 treatment arms. 
The main differences in the tolerability profile of capecitabine
compared with CMF were a higher incidence of grade 3 hand-foot
syndrome (15% vs 0%, respectively) and more cases of grade 3
diarrhoea (8% vs 3%, respectively, with no grade 4 diarrhoea in
either group). However, both of these adverse events were gener-
ally of mild to moderate nature and could be managed by treat-
ment interruption or dose adjustment if appropriate. The incidence
of grade 3 or 4 neutropenia was considerably higher in patients
treated with CMF (41% compared with only 8% in the
capecitabine group), and alopecia also occurred more frequently
with CMF than capecitabine. 
The encouraging antitumour activity and tolerability profile
observed with capecitabine in these trials has significant implica-
tions for treatment, both in first-and second-line regimens, and
also in patients failing anthracyclines and/or taxoids. Capecitabine
therapy may also result in fewer interventions and hospitaliza-
tions. 
Other oral fluoropyrimidines are under active study but
capecitabine is the dominant agent of interest, partly because it is
the first of the class to be approved by the FDA in the USA and
appears to be the nearest to licensing in Europe. 2 other agents,
UFT and S1, are in clinical development. Both of these agents
contain DPD inhibitors (uracil in UFT and 5-chloro-2, 4-
dihydropyrimidine [CDHP] in S1), which complete directly with
5-FU for the uracil binding site of DPD. The effect of competitive
DPD inhibition is to increase the proportion of 5-FU available for
anabolism to cytotoxic compounds and reduce the proportion
catabolized to inactive compounds. The clinical development of
another DPD inhibitor, eniluracil, which had been investigated in
combination with oral 5-FU, has recently been abandoned. 
CONCLUSIONS 
Despite the development of new anti cancer agents in the last few
years, the expectations of a significant impact on the treatment of
advanced breast cancer clearly have not been fully met. There is a
need for new therapies that are of comparable efficacy but better
tolerated than the taxoids. These new agents would provide alter-
natives to taxoids both in first- and second-line regimens and for
patients with breast cancer that is unresponsive or refractory to
taxoids. 
Until recently, the treatment alternatives to taxoids were very
limited. However, results from studies in advanced breast cancer
of the new, oral, enzymatically activated fluoropyrimidine,
capecitabine, indicate that this agent may be useful when anthracy-
cline-based chemotherapy fails as well as in taxoid failures.
Capecitabine may offer an effective, well-tolerated and more
convenient alternative to taxoids and other intravenous cytotoxic
agents. Clinical trials of capecitabine in breast cancer have demon-
strated substantial activity with durable responses and meaningful
clinical benefits. 
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capecitabine may be useful as second-line therapy in anthracy-
cline-resistant metastatic breast cancer or as first-line treatment as
an alternative to intravenous chemotherapy. The improvement of
patients’ quality of life achieved by using oral agents with similar
efficacy but enhanced tolerability is a vital component of the care
of cancer patients where the goal of treatment is palliation.
Furthermore, the low incidence of myelosuppression makes
capecitabine an attractive agent for use in the adjuvant setting and
also for incorporation into combination regimens, either with
conventional agents, for example epirubicin/doxorubicin, or
agents such as the taxoids and vinorelbine. 
Most recently, data from a large, randomized, phase III trial
have shown that the addition of capecitabine to docetaxel in
anthracycline-pretreated patients results in significantly superior
overall survival compared with docetaxel monotherapy as well as
significantly superior response rates and time to disease progres-
sion (O’Shaughnessy et al, 2000). Clearly capecitabine as
monotherapy or in combination with other cytotoxic agents
provides an important new treatment option for metastatic breast
cancer, combining convenience and a favourable side-effect
profile with high activity. New data from ongoing monotherapy
and combination trials are eagerly awaited. 
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